一项多中心试点研究：使用缓释型纳曲酮注射剂治疗曾有阿片类药物依赖史的假释犯和缓刑犯。
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
机构信息
University of Pennsylvania, Philadelphia, Pennsylvania, USA. coviello
出版信息
Subst Abus. 2012;33(1):48-59. doi: 10.1080/08897077.2011.609438.
Abstract
A feasibility study was conducted to pilot test the ability of 5 sites to recruit, treat, and retain opioid-dependent offenders in a trial of extended-release injectable naltrexone (XR-NTX). The participants, 61 previously opioid-dependent individuals under legal supervision in the community, received up to 6 monthly injections of Depotrex brand naltrexone and completed a 6-month follow-up interview. Six-month outcomes showed that those who completed treatment had significantly fewer opioid-positive urines and were less likely to have been incarcerated than those who had not completed treatment. The findings indicate that XR-NTX holds promise as a feasible, effective treatment option for opioid-dependent offenders.
摘要
一项可行性研究旨在对 5 个地点进行试点测试，以评估它们在一项扩展释放型纳曲酮（XR-NTX）试验中招募、治疗和留住阿片类药物依赖罪犯的能力。参与者为 61 名先前在社区中受到法律监管的阿片类药物依赖个体，他们接受了多达 6 次 Depotrex 品牌纳曲酮的每月注射，并完成了 6 个月的随访访谈。6 个月的结果表明，完成治疗的患者尿液中阿片类药物阳性的情况明显减少，且被监禁的可能性也低于未完成治疗的患者。这些发现表明，XR-NTX 有望成为一种可行且有效的阿片类药物依赖罪犯治疗选择。
相似文献
1
A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers.
Subst Abus. 2012;33(1):48-59. doi: 10.1080/08897077.2011.609438.
2
A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.
J Subst Abuse Treat. 2015 Dec;59:52-8. doi: 10.1016/j.jsat.2015.07.005. Epub 2015 Jul 18.
3
Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
J Subst Abuse Treat. 2018 Feb;85:45-48. doi: 10.1016/j.jsat.2017.04.010. Epub 2017 Apr 19.
4
Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
Drug Alcohol Depend. 2012 Jan 1;120(1-3):48-54. doi: 10.1016/j.drugalcdep.2011.06.023. Epub 2011 Jul 22.
5
Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Drug Alcohol Depend. 2014 May 1;138:83-8. doi: 10.1016/j.drugalcdep.2014.02.002. Epub 2014 Feb 15.
6
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
J Addict Med. 2015 May-Jun;9(3):238-43. doi: 10.1097/ADM.0000000000000125.
7
Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Addiction. 2018 Jul;113(7):1188-1209. doi: 10.1111/add.14180. Epub 2018 Mar 24.
8
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Contemp Clin Trials. 2014 Nov;39(2):256-68. doi: 10.1016/j.cct.2014.09.002. Epub 2014 Sep 18.
9
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
J Addict Med. 2017 May/Jun;11(3):224-230. doi: 10.1097/ADM.0000000000000302.
10
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634.
引用本文的文献
1
Design of a pragmatic clinical trial to improve screening and treatment for opioid use disorder in primary care.
Contemp Clin Trials. 2023 Jan;124:107012. doi: 10.1016/j.cct.2022.107012. Epub 2022 Nov 17.
2
A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
Subst Abus. 2022;43(1):556-563. doi: 10.1080/08897077.2021.1975867. Epub 2021 Sep 29.
3
A pilot study of the functionality and clinician acceptance of a clinical decision support tool to improve primary care of opioid use disorder.
Addict Sci Clin Pract. 2021 Jun 15;16(1):37. doi: 10.1186/s13722-021-00245-7.
4
Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity.
J Pharmacol Exp Ther. 2020 Sep;374(3):392-403. doi: 10.1124/jpet.120.000014. Epub 2020 Jun 25.
5
Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.
J Gen Intern Med. 2020 Sep;35(9):2529-2536. doi: 10.1007/s11606-020-05944-6. Epub 2020 Jun 24.
6
Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation.
Health Justice. 2020 Mar 14;8(1):7. doi: 10.1186/s40352-020-0106-9.
7
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Addict Sci Clin Pract. 2019 Oct 1;14(1):37. doi: 10.1186/s13722-019-0166-0.
8
Treatment Retention Satisfaction, and Therapeutic Progress for Justice-Involved Individuals Referred to Community-Based Medication-Assisted Treatment.
Subst Use Misuse. 2019;54(9):1461-1474. doi: 10.1080/10826084.2019.1586949. Epub 2019 Apr 29.
9
Clinical evaluation of deep brain stimulation of nucleus accumbens/anterior limb of internal capsule for opioid relapse prevention: protocol of a multicentre, prospective and double-blinded study.
BMJ Open. 2019 Feb 13;9(2):e023516. doi: 10.1136/bmjopen-2018-023516.
10
The neurobiology of addiction.
Ann N Y Acad Sci. 2019 Sep;1451(1):5-28. doi: 10.1111/nyas.13989. Epub 2019 Jan 15.
本文引用的文献
1
Buprenorphine-naloxone Treatment for Pre-release Opioid-dependent Inmates in Puerto Rico.
J Addict Med. 2007 Sep;1(3):126-32. doi: 10.1097/ADM.0b013e31814b8880.
2
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.
3
A randomized trial of oral naltrexone for treating opioid-dependent offenders.
Am J Addict. 2010 Sep-Oct;19(5):422-32. doi: 10.1111/j.1521-0391.2010.00070.x.
4
An integrated drug counseling and employment intervention for methadone clients.
J Psychoactive Drugs. 2009 Jun;41(2):189-97. doi: 10.1080/02791072.2009.10399912.
5
Predictors of drug treatment completion among parole violators.
J Psychoactive Drugs. 2009 Jun;41(2):173-80. doi: 10.1080/02791072.2009.10399910.
6
Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.
Drug Alcohol Depend. 2009 Nov 1;105(1-2):83-8. doi: 10.1016/j.drugalcdep.2009.06.015. Epub 2009 Jul 21.
7
Interventions to promote successful re-entry among drug-abusing parolees.
Addict Sci Clin Pract. 2009 Apr;5(1):4-13. doi: 10.1151/ascp09514.
8
Methadone maintenance 4 decades later: thousands of lives saved but still controversial.
JAMA. 2008 Nov 19;300(19):2303-5. doi: 10.1001/jama.2008.648.
9
Why don't out-of-treatment individuals enter methadone treatment programmes?
Int J Drug Policy. 2010 Jan;21(1):36-42. doi: 10.1016/j.drugpo.2008.07.004. Epub 2008 Sep 20.
10
Attitudes toward buprenorphine and methadone among opioid-dependent individuals.
Am J Addict. 2008 Sep-Oct;17(5):396-401. doi: 10.1080/10550490802268835.
Zotero 插件